Unique Cardiac Biomarker VectraCor holds a patented Cardiac Electrical Biomarker technology that enables real-time AMI detection and multi-lead ECG derivation from a compact setup, presenting a unique value proposition for hospitals and emergency departments seeking earlier intervention capabilities.

5-Electrode Advantage The Vectraplex system delivers 15-lead ECG (US) and 22-lead ECG (EU) using only five electrodes, enabling streamlined monitoring with potential for reduced setup time, which can appeal to busy telemetry units and EMS partners.

EMS and Cardiology Focus Target markets include cardiology and emergency medicine, with potential expandability into hospital bedside monitors, stroke/AMI pathways, and pre-hospital care collaborations where early detection can improve outcomes and workflow efficiency.

Growth through QRS As parent to QRS Diagnostics, there are adjacent opportunities to cross-sell PC-based cardio-pulmonary devices (ECGs and spirometers), leveraging existing relationships in hospitals and clinics to broaden product adoption.

Financial and Scale Opportunity With global patents and published research backing disruptive technology, there is potential to pursue partnerships or pilot programs with mid-to-large healthcare systems seeking innovative monitoring solutions, complemented by a scalable GTM strategy to attract distributors and regional integrators.